Home FDA labels 19c756eb-7a78-408f-d003-0d13d95e508a FDA label 19c756eb-7a78-408f-d003-0d13d95e508a openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID 29c13b5d-ece4-d0a9-d50a-1629c71d00b9
SPL ID 19c756eb-7a78-408f-d003-0d13d95e508a
Version 10
Effective date 2019-01-11
Source export date 2026-10-12
Source partition 1
Source file https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-10-12/7928c8e8c6256620071a8b7e5b93eb8dfa543649c08d17a01ea02251012ba58c/drug-label-0001-of-0014.json.zip
Source manifest SHA-256 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run 20261013T011858Z
Imported at 2026-10-13 01:26:17 Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 2 matching rows.
adverse reactions ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Perioral dermatitis Itching Allergic contact dermatitis Irritation Maceration of the skin Dryness Secondary infection Folliculitis Skin atrophy Hypertrichosis Striae Acneiform eruptions Miliaria Hypopigmentation
adverse reactions table <table width="60%"> <col align="left" valign="top" width="45%"/> <col align="left" valign="top" width="55%"/> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Burning</td> <td styleCode="Rrule">Perioral dermatitis</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Itching</td> <td styleCode="Rrule">Allergic contact dermatitis</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Irritation</td> <td styleCode="Rrule">Maceration of the skin</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dryness</td> <td styleCode="Rrule">Secondary infection</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Folliculitis</td> <td styleCode="Rrule">Skin atrophy</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hypertrichosis</td> <td styleCode="Rrule">Striae</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Acneiform eruptions</td> <td styleCode="Rrule">Miliaria</td> </tr> <tr> <td styleCode="Lrule Rrule">Hypopigmentation</td> <td styleCode="Rrule"/> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.